NCT06800651RecruitingPhase 2
Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Source: ClinicalTrials.gov · Last updated 3 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants with Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 135 (estimated)
- First submitted
- 20 Jan 2025
- Start date
- 13 Mar 2025
- Primary completion date
- 28 Feb 2027
- Lead sponsor
- Jemincare
- Diseases
- Polycystic kidney disease
- NCT number
- NCT06800651
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 135
- From 13 Mar 2025 to the primary completion date, 28 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 12 weeks prior to screening, patients had taken tolvaptan or another ADPKD improvers, or patients who were assessed by the investigator to be likely to use diuretic during the trial period;
- Patients who have previously received decompression surgery for renal cysts; or who received major surgery within 12 weeks before signing the ICF;
Other
- Praticipants who are unable to feel thirst, or have difficulty with fluid/food intake;
- The investigator think that the praticipant is unable to comply with the requirements of the trial or cannot be evaluated by the trial.
Who the study is looking for
- Able to understand the procedures of this trial and provide written informed consent voluntarily;
- Age between 18 to 55 years, male or female;
- ADPKD diagnostic criteria were met before randomization;
- Rapidly progressive ADPKD criteria were met.
Age in the registry: 18 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.